Huong Hoang1, Bjarne Laursen2, Elsebeth N Stenager3, Egon Stenager4. 1. Institute of Regional Health Research. University of Southern Denmark/ MS-clinic (Sønderborg, Esbjerg, Vejle) of Southern Jutland, Department of Neurology, Sønderborg, Denmark. Research Unit of Mental Health, Odense,Åbenrå, Denmark Huong.Hoang@rsyd.dk. 2. National Institute of Public Health, University of Southern Denmark, Copenhagen, Denmark. 3. Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark/ Research Unit of Mental Health, Åbenrå, Odense, Denmark. Åbenrå, Denmark. 4. Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark/ MS-clinic (Sønderborg, Esbjerg, Vejle) of Southern Jutland, Department of Neurology, Sønderborg, Denmark.
Abstract
BACKGROUND: Studies of depression and anxiety in multiple sclerosis (MS) patients have reported higher rates in MS patients than the general population. OBJECTIVE: To estimate the risk of depression and anxiety and the use of tricyclic antidepressant and selective serotonin reuptake inhibitors (SSRI) prescriptions, in the pre-diagnostic and the post-diagnostic period of MS compared to the background population. METHODS: A cohort of 5084 MS patients was included and matched with a control population of 24,771 persons linked to nationwide registers. Logistic regression analyses were performed estimating odds ratios (OR). RESULTS: In the pre-diagnostic period, the OR for having a diagnosis of depression and anxiety is 1.4 (95% confidence interval (CI) =1.05-1.88), and the OR of redemption prescriptions of TCAs is 1.90 (CI=1.54-2.34) and OR is 1.34 (CI= 1.20-1.51) for SSRI. In the post-diagnostic period the OR is 1.23 (CI= 0.92-1.64) for depression and anxiety diagnosis. The OR is 6.70 (CI=5.81-7.72) for TCA and OR is 2.46 (CI= 2.25-2.69) for SSRI. CONCLUSION: During both the pre- diagnostic and post-diagnostic period, MS patient have increased risk of depression and anxiety diagnoses and redemption of antidepressant and anxiolytic prescriptions, compared to the background population.
BACKGROUND: Studies of depression and anxiety in multiple sclerosis (MS) patients have reported higher rates in MSpatients than the general population. OBJECTIVE: To estimate the risk of depression and anxiety and the use of tricyclic antidepressant and selective serotonin reuptake inhibitors (SSRI) prescriptions, in the pre-diagnostic and the post-diagnostic period of MS compared to the background population. METHODS: A cohort of 5084 MSpatients was included and matched with a control population of 24,771 persons linked to nationwide registers. Logistic regression analyses were performed estimating odds ratios (OR). RESULTS: In the pre-diagnostic period, the OR for having a diagnosis of depression and anxiety is 1.4 (95% confidence interval (CI) =1.05-1.88), and the OR of redemption prescriptions of TCAs is 1.90 (CI=1.54-2.34) and OR is 1.34 (CI= 1.20-1.51) for SSRI. In the post-diagnostic period the OR is 1.23 (CI= 0.92-1.64) for depression and anxiety diagnosis. The OR is 6.70 (CI=5.81-7.72) for TCA and OR is 2.46 (CI= 2.25-2.69) for SSRI. CONCLUSION: During both the pre- diagnostic and post-diagnostic period, MSpatient have increased risk of depression and anxiety diagnoses and redemption of antidepressant and anxiolytic prescriptions, compared to the background population.
Authors: Adil Harroud; Ruth Ann Marrie; Kathryn C Fitzgerald; Amber Salter; Yi Lu; Mitulkumar Patel; Kaarina Kowalec Journal: Mult Scler Date: 2021-02-16 Impact factor: 6.312
Authors: Maria Luca; Clara Grazia Chisari; Aurora Zanghì; Francesco Patti Journal: Int J Environ Res Public Health Date: 2021-05-24 Impact factor: 3.390